Pay in 4 interest-free payments of $6.02 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Slower digestion also allows for less instances of blood sugar spikes
Risk ratios (RR) for MACE estimates according to direct (DPP-4 inhibitors, GLP-1RA and SGLT-2 inhibitors against placebo) and indirect (DPP-4 inhibitors vs GLP-1RA or SGLT-2 inhibitors, and GLP-1RA vs SGLT-2 inhibitors) comparisons
Its FDA-approved for weight loss and still being studied for diabetes
Gut bacteria alleviate smoking-related NASH by degrading gut nicotine
Other Trials # Other interesting and active GLP analog trials include: Parkinsons Disease (NCT03659682) Alcohol-related Liver Disease (NCT06409130) Acute Ischemic Stroke (NCT05630586) Polycystic Ovary Syndrome (NCT05646199, NCT05702905, and more) For a literature review and deeper dive on this topic focused on research, see From diabetes to diverse domains: the multifaceted roles of GLP-1 receptor agonists 7
US$ 22.83
US$ 24.88
US$ 20.06
